Zobrazeno 1 - 10
of 2 371
pro vyhledávání: '"targeted agents"'
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background The present study aimed to investigate physicians’ perspectives on the diagnosis and treatment decisions for patients with non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) exon 20 insertion (
Externí odkaz:
https://doaj.org/article/b1ae1466d33e420d8c2049daf1d40efe
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundTransarterial chemo(embolization) is preferred for treating unresectable hepatocellular carcinoma (uHCC); however, because of emerging immune-targeted therapies, its efficacy is at stake. This systematic review pioneers to evaluate the clin
Externí odkaz:
https://doaj.org/article/fdbad755322d4598b783b6f0196ddecb
Publikováno v:
Pharmaceuticals, Vol 17, Iss 10, p 1298 (2024)
Direct-acting anti-infective drugs target pathogen-coded gene products and are a highly successful therapeutic paradigm. However, they generally target a single pathogen or family of pathogens, and the targeted organisms can readily evolve resistance
Externí odkaz:
https://doaj.org/article/34ce56c71f8f4d92b746cf6076ce7ad5
Autor:
Keina Nozaki, Hisashi Matsushima, Hiyo Obikane, Ryohei Nishimoto, Ryo Tanaka, Takeru Morishige, Tomoko Masuda, Haruki Kume
Publikováno v:
IJU Case Reports, Vol 6, Iss 6, Pp 329-333 (2023)
Introduction Disseminated carcinomatosis of the bone marrow in prostate cancer is rare and has a poor prognosis. Although strong evidence suggests that novel hormonal agents improve the prognosis of metastatic prostate cancer, their effectiveness in
Externí odkaz:
https://doaj.org/article/7ca780e084694444b0e26f409f5c5956
Autor:
Naoshi Nishida, Masatoshi Kudo
Publikováno v:
Liver Cancer, Pp 1-14 (2023)
Background: Intrahepatic cholangiocarcinoma (iCCA) is often diagnosed at an advanced stage, leading to limited treatment options and a poor prognosis. So far, standard systemic therapy for advanced iCCA has been a combination of gemcitabine and cispl
Externí odkaz:
https://doaj.org/article/afca5ee737d0431ab8c8d7797f7b80dd
Publikováno v:
Zhongguo aizheng zazhi, Vol 33, Iss 9, Pp 879-888 (2023)
Recently, targeted therapy has become the standard of care for advanced thyroid cancer. Although expert consensus on the management of adverse events in patients receiving targeted agents for radioactive iodine-refractory differentiated thyroid cance
Externí odkaz:
https://doaj.org/article/0f5a3f8785b44ca49b76adeeb76f32db
Publikováno v:
Clinical and Molecular Hepatology, Vol 29, Iss 3, Pp 593-604 (2023)
Recently, treatments for unresectable hepatocellular carcinoma (HCC) have undergone remarkable development. Various systemic chemotherapy drugs have been approved and are recommended by clinical guidelines worldwide. Although systemic treatments are
Externí odkaz:
https://doaj.org/article/bd1da7d0a4a84d15825c712ab35d4879
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 10, Pp 949-958 (2023)
Jing Li,1,2,* Liang Huang,1,* Chao Ge,3,* Xingwu Zhu,1 Maixuan Qiu,1 Chaopan Chen,3 Shaohua Wei,2 Yiqun Yan1 1Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, People’s Republic of China; 2Department of Ge
Externí odkaz:
https://doaj.org/article/140a9a1517574db28d5f80f6843d6f0e
Autor:
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi
Publikováno v:
Clinical and Molecular Hepatology, Vol 29, Iss 2, Pp 242-251 (2023)
Striking advances in systemic therapy for unresectable advanced hepatocellular carcinoma (HCC) have improved the average prognosis of patients with HCC. As a result, the guidelines for the treatment of HCC have changed significantly. However, various
Externí odkaz:
https://doaj.org/article/857fd30faa134a169757cc9f714c6306
Autor:
Neele Wüstmann, Konstantin Seitzer, Verena Humberg, Julia Vieler, Norbert Grundmann, Julie Steinestel, Dorothee Tiedje, Stefan Duensing, Laura-Maria Krabbe, Martin Bögemann, Andres Jan Schrader, Christof Bernemann, Katrin Schlack
Publikováno v:
Biomarker Research, Vol 11, Iss 1, Pp 1-14 (2023)
Abstract Background Androgen receptor (AR) splice variants (AR-Vs) have been discussed as a biomarker in prostate cancer (PC). However, some reports question the predictive property of AR-Vs. From a mechanistic perspective, the connection between AR
Externí odkaz:
https://doaj.org/article/2099e95770b44143932183ee7f6b5264